Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

Science Corporation, led by former Neuralink co-founder Max Hodak, has successfully implanted its PRIMA vision-restoring chip into its first patient suffering from Stargardt disease. The announcement, made at TechCrunch Disrupt, marks a significant milestone in the company's efforts to develop advanced brain-computer interfaces (BCI) aimed at treating blindness. The PRIMA system is designed to bypass damaged photoreceptors in the retina, using a sub-retinal implant that receives visual information from a pair of camera-equipped glasses. By stimulating the remaining healthy neurons, the device aims to restore functional vision for patients with macular degeneration. This procedure represents a critical step forward for Science Corporation as it seeks to validate its technology in clinical settings. The company continues to refine its BCI platform, positioning itself as a key player in the intersection of neurotechnology and restorative medicine, with further trials expected to provide more data on the long-term efficacy of the implant.